全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Rui Bergantim , Manuel Neves ...
来源:[J].Annals of Hematology(IF 2.866), 2019, Vol.98 (7), pp.1689-1701Springer
摘要:Abstract(#br)Patients older than 75 years old with multiple myeloma (MM) have shorter survival and are usually treated differently from what features in clinical trials. In this study, the authors characterized the Portuguese population of MM patients above 75 years old, tre...
作者:Rui Bergantim , Elisabete Rios ...
来源:[J].Clinical Drug Investigation(IF 1.915), 2013, Vol.33 (1), pp.51-55Springer
摘要:Abstract(#br)The authors report the case of a 58-year-old female patient with a life-threatening invasive fungal disease caused by a coinfection of Aspergillus and Mucor species that occurred during induction and consolidation chemotherapy for an acute myeloid leukemia. The disea...
作者:Rui Bergantim , Juliana Bastos ...
来源:[J].Case Reports in Hematology, 2020, Vol.2020Hindawi
摘要:Extramedullary disease is an aggressive presentation at diagnosis and relapse for multiple myeloma (MM) patients. Central nervous system (CNS) is a very rare manifestation of the extramedullary disease, accounting for less than 1% of MM on diagnosis and relapse. Neurological...
作者:Rui Bergantim , Jose E. Guimaraes
来源:[J].Current Pharmaceutical Biotechnology(IF 2.69), 2014, Vol.15 (5), pp.492-502Bentham
摘要:miR-128 has been associated with cancer, particularly with leukemia. In particular, this miR has been described,together with other miRs, to allow the discrimination between AML (acute myeloid leukemia) and ALL (acutelymphoblastic leukemia). In addition, miR-128 is included ...
作者:Rui Bergantim , Jose E. Guimaraes
来源:[J].Current Pharmaceutical Biotechnology(IF 2.69), 2014, Vol.15 (5), pp.492-502Bentham
摘要:miR-128 has been associated with cancer, particularly with leukemia. In particular, this miR has been described,together with other miRs, to allow the discrimination between AML (acute myeloid leukemia) and ALL (acutelymphoblastic leukemia). In addition, miR-128 is included ...
作者:Rui Bergantim , Hugo R. Caires ...
来源:[J].Cancers, 2020, Vol.12 (2)MDPI
摘要:Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies. Survival outcomes have improved sub...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×